Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

OBJECTIVE: Apatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Jinglei, He, Xin, Luo, Ying, Yu, Ping, Chen, Ying, Liu, Jing, Wang, Xin, Wang, Chang, Liang, Tingting, Bai, Yuxian, Han, Yu, Man, Li, Leng, Chuanchun, Zhou, Caiyun, He, Lijie, Liu, Yunpeng, Qu, Xiujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166633/
https://www.ncbi.nlm.nih.gov/pubmed/37168383
http://dx.doi.org/10.3389/fonc.2023.1072943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166633/
https://www.ncbi.nlm.nih.gov/pubmed/37168383
http://dx.doi.org/10.3389/fonc.2023.1072943

Ejemplares similares